Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

ABSTRACT:

SUBMITTER: Jackson GH 

PROVIDER: S-EPMC7043012 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature